GH Research PLC (GHRS) - Total Liabilities
Based on the latest financial reports, GH Research PLC (GHRS) has total liabilities worth $12.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of GH Research PLC's assets are long-term investments to see how much of total assets are deployed in long-term investments.
GH Research PLC - Total Liabilities Trend (2019–2025)
This chart illustrates how GH Research PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GH Research PLC total assets.
GH Research PLC Competitors by Total Liabilities
The table below lists competitors of GH Research PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gudang Garam Tbk
JK:GGRM
|
Indonesia | Rp13.78 Trillion |
|
China Enterprise Co Ltd
SHG:600675
|
China | CN¥34.01 Billion |
|
Sichuan Teway Food Group Co Ltd
SHG:603317
|
China | CN¥1.14 Billion |
|
Guangdong Ellington Electronics Technology Co Ltd
SHG:603328
|
China | CN¥2.33 Billion |
|
Ruentex Industries Ltd
TW:2915
|
Taiwan | NT$13.26 Billion |
|
Wenzhou Yihua Connector Co Ltd
SHE:002897
|
China | CN¥4.27 Billion |
|
Spectrum Brands Holdings Inc
NYSE:SPB
|
USA | $1.67 Billion |
|
Alsea S.A.B. de C.V
MX:ALSEA
|
Mexico | MX$70.00 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down GH Research PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See GH Research PLC net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GH Research PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GH Research PLC (2019–2025)
The table below shows the annual total liabilities of GH Research PLC from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.53 Million | -8.53% |
| 2024-12-31 | $9.32 Million | +27.14% |
| 2023-12-31 | $7.33 Million | +61.28% |
| 2022-12-31 | $4.55 Million | +65.37% |
| 2021-12-31 | $2.75 Million | +1017.48% |
| 2020-12-31 | $246.00K | +136.54% |
| 2019-12-31 | $104.00K | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more